Steatohepatitis/Metabolic Liver Disease News

Arrowhead Pharmaceuticals Inc. announced 24-week liver biopsy results in patients from an open-label phase 2 clinical study of ARO-AAT, a second-generation investigational RNA interference therapeutic intended for treatment of a liver disease associated with alpha-1 antitrypsin deficiency.

Young women with nonalcoholic fatty liver disease had higher testosterone levels, which led to a twofold higher risk for nonalcoholic steatohepatitis and fibrosis, according to study results.

Poxel SA announced positive results for the phase 2a trial of PXL770 for the treatment of nonalcoholic steatohepatitis, according to a press release.

Opioid use was more common in patients with nonalcoholic fatty liver disease with cirrhosis, higher BMI and psychiatric disease, according to a study published in Digestive Diseases.

Compared with men, women had a significantly higher frequency of underlying nonalcoholic fatty liver disease and noncirrhotic hepatocellular carcinoma, according to data published in the American Journal of Gastroenterology.

Patients with non-alcoholic fatty liver disease are more likely to develop diabetes, according to a meta-analysis published in Gut.

Chronic liver diseases, including decompensated cirrhosis and hepatocellular carcinoma, were associated with increased mortality in patients with COVID-19, according to study results.

Lean Asian patients with nonalcoholic fatty liver disease had significantly lower prevalence of cirrhosis, cardiovascular disease and metabolic abnormalities than lean non-Asian patients.

Galectin Therapeutics has begun a phase 2b/3 clinical trial of belapectin to treat cirrhosis in patients with nonalcoholic steatohepatitis.

Two dosages of nidufexor were safe and correlated with significant reductions in alanine aminotransferase levels, hepatic fat fraction and body weight in patients with nonalcoholic steatohepatitis, according to research presented at The Digital International Liver Congress.